Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BICO, Audiocast with teleconference, Q3'24

By Inderes11/26/2024, 9:00 AM
BICO Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Maria Forss
00:01 - 03:51

Hello and a warm welcome, everyone, to BICO's third earnings call for 2024, where we will present our quarter three 2024 report. My name is Maria Forss, and I'm the President and CEO of BICO. And together with our CFO Jacob Thordenberg, I will present our report. Today's agenda is divided into five sections. Before the Q&A, we will begin to summarize the quarter and highlight significant events. We have also had some recent events which we will comment upon, even if they occurred after the end of quarter three. We will further comment on the market development and thereafter present the quarter three financial performance as well as deep dives into our business areas' performances. This will be followed by a presentation of the development of our strategic priorities. Strategic agenda and financial targets. And these sections will be in listening-only mode. After the presentation, we invite you to our Q&A session. And the financial hearing's host will be back with further instructions. Before presenting a summary of the quarter, I would like to briefly recap one of our main events this year. Namely, our Capital Markets Day, which took place in mid-September. The main purpose of the Capital Markets Day was to launch our updated strategy, which essentially entailed a new vision and mission. Our four strategic priorities and financial targets were reiterated. Our key priority, commercial excellence, has been reinforced with five focus areas, and we also launched a new business area structure with Lab Automation, Life Science Solutions, and Bioprinting. From this quarter, they also constitute our reporting segments. If you haven't watched yet, just click on the QR code to access the recordings from the digital sessions, and they can also be found on our website. Let us now move into the quarter for quarter three. We can conclude a soft market for instrument sales, primarily in academia and diagnostics segments due to CAPEX constraints and fewer project starts in Lab Automation. All in all, this hampered our quarter three sales performance. It's important to highlight that Lab Automation, i.e., BICO has a project-based business with significant fluctuations in revenues between quarters. Hence, it's more relevant to look at year-to-date figures where we have delivered 26% organic growth. We continue to see a strong trend and demand for integrated Lab Automation solutions. And the decline in sales also impacted profitability, which was partly offset by strict cost control. We delivered sales of 496 million and experienced an organic growth decline of -13%, compared to a very strong corresponding quarter last year. Yakov will give you more details on the financials later on in this presentation. All business areas were profitable in quarter three, reporting a total adjusted EBITDA for the Group of 14 million, generating an adjusted EBITDA margin of 8%. The operating cash flow for the quarter was 45 million. Thanks to the development in net working capital and as mentioned on the previous slide, we also launched our updated strategy. Our new general counsel, Andreas Joersjö, was announced in July and he joined us in October. His previous experience in a commercial mindset will further contribute to developing our legal function. In addition, a few but important events occurred after the end of the quarter. Last Thursday, we announced that we have entered into an agreement to divest Nanoscribe. We have repurchased convertible bonds, and we have also announced further rightsizing and launched a sharpened commercial agenda in CELLINK. I will now hand over to Jacob to comment on the first two events which occurred after the quarter.

Jacob Thordenberg
03:52 - 07:50

Thank you, Maria. We announced last week, on November 21st, that we have entered into an agreement to divest Nanoscribe, which is a company in our Bioprinting business. Nanoscribe, based in Karlsruhe, Germany, is a producer of hardware equipment used in the microfabrication segment, with customers mainly outside the life science industry. As per LTM Q3 2024, Nanoscribe recorded $230 million in sales, a gross margin of 54%, an adjusted EBITDA margin of 12%, and a working capital level in relation to LTM sales of 24%. BICO AB acquired Nanoscribe in May 2021, and the total acquisition value was $250 million in cash and circa 301,000 Veeco shares. Additionally, between 2021 and 2023, approximately 132 million has been paid in earnouts. The acquisition rationale at the time was to access nanoscale printing technology as a complement to the bioprinting offering. The enterprise value on a cash and debt-free basis amounts to €28.6 million, corresponding to circa 323 million Swedish kronor. Following net debt and working capital adjustments. The equity value amounts to €26 million, corresponding to approximately 294 million Swedish kronor. The divestment is estimated to generate a capital gain of approximately 10% above book value per Q3, subject to the timing of the closing of the transaction and FX movements. The final financial impact will be reported in the interim report for Q4 2024, and Nanoscribe will be treated as discontinued operations in BICO's financials from Q4 2024. The rationale behind the divestment is in line with the updated strategy where Nanoscribe has been concluded as non-core due to its significant footprint outside the life science industry. Net proceeds from the divestment, following transaction expenses, will be used to reduce long-term debt. This is a good segue into the next slide on the repurchasing of convertible debt. But before moving on to that, I would like to conclude and refer to what we communicated during our Capital Markets Day in September. We continue to receive serious interest for many assets in our portfolio, and BICO will continue to review our portfolio of assets to maximize execution on our updated strategy and shareholder value. Now, let's move on to the next slide. First, to give you some background, in March 2021, BICO issued senior unsecured convertible bonds with a total nominal amount of 1.5 billion Swedish kronor. On November 22nd, BICO repurchased convertible bonds with a total nominal amount of 118 million at a purchase price of 83.6% of the convertible nominal amount. The total purchase consideration for the bought-back convertible bonds thereby amounted to 98.7 million Swedish kronor. Following the buyback, BICO's holdings of the convertible bonds total a nominal amount of 118 million. The rationale behind the buyback was to optimize BICO's capital structure, i.e. Reduce long-term debt, which was made possible by our strong liquidity position. BICO will continue to evaluate the bond market and may from time to time repurchase further convertible bonds in the market if deemed attractive. I will now hand back to Maria.

Maria Forss
07:51 - 10:44

Thank you. And this means that we have reached the third and final event, which occurred after quarter three that we would like to highlight. Yesterday evening, we announced further rightsizing and launched a sharpened commercial agenda for CELLINK. The launched plan focuses on long-term stability and profitability, and this entails a sharpened commercial agenda and further right-sizing to achieve a sustainable cost structure. The measures taken will result in a solid platform to scale from and lay the foundation for sustainable, profitable growth. It will also entail an increased focus on the technologies where CELLINK has a leading market position and optimize synergies with other companies, which is in line with the group's updated strategy. The right sizing is expected to result in the redundancy of approximately 20% of the employees across the CELLINK organisation, and redundancies are subject to union negotiations. All in all, these three events show that we are focused on delivering on our updated strategy and on our four strategic priorities. I will now move on to the next section. Market development. This section was introduced in quarter one this year and gives more flavor to the market development. Now, I will also comment on sales per geography. The market environment continues to be challenging and uncertain with regards to demand, as well as macroeconomic and geopolitical factors. We are a few weeks post the U.S. election, which took place after the end of the period, and we will monitor and stay proactive regarding any potential negative impacts from tariffs or other trade barriers. Our exposure in Asia, including China, is, however, limited, representing only 6% of sales in quarter three. This is a decline of 12% in units compared to the corresponding quarter last year, which also impacted our sales levels. The slower market in China is also reported by many of our peers, and it's indirectly impacting our business. For quarter three, we can conclude the pattern we have seen for some time, i.e., That customers are holding tight to their CapEx spending, and this has impacted our sales levels compared with those of our peers who are less dependent on instrument sales. However, we see improved sales development in our companies that are more focused on consumable sales. As you can see on the map, the distribution of sales changed during the quarter due to the significant drop in Asia, particularly in China. Sales in Europe have increased in relation to North America due to fewer project starts for Lab Automation during the quarter, and despite the short-term challenges that BICO faces, we believe that we are well positioned with our updated strategy and we focus on commercial effectiveness. It's now time for me to hand over to Jacob again for a summary of our financial performance.

Jacob Thordenberg
10:45 - 16:42

Thank you, Maria. Yes, I will now comment on the third quarter of 2024. All numbers are presented in Swedish crowns. I would also like to remind you that from the first quarter of this year, BICO reports in functional reporting and comparable numbers have been adjusted. Furthermore, all organic growth figures are in constant currency. As Maria mentioned, BICO delivered sales of 496 million with an organic growth of -13%. And I will comment more on sales on the next slide. Adjusted EBITDA amounted to 40 million, and EBITDA was 37 million for the quarter. We also have a separate slide where I will present the Q3 EBITDA development. Gross margin for the quarter amounted to 53%, which is an improvement compared to previous quarters and can be explained by the product mix with fewer projects. The project-related business in Lab Automation. The net loss for the quarter amounted to -248 million. On the next slide, I will comment on sales for the group for the third quarter. As mentioned, the third quarter generated sales of 496 million, corresponding to a negative sales growth of 16% and a negative organic growth of 13%, compared to a very strong corresponding quarter last year. Year to date, sales amounted to 1,540,000,000, corresponding to a negative organic growth of 4% compared to last year. In the quarter, the market has continued to be soft for instrument sales, primarily in the academia, research, and diagnostic segments due to ongoing customer CapEx constraints. Additionally, during the quarter, we had fewer project starts in Lab Automation, negatively impacting our sales. As mentioned in our CMD, one of the rationales for including Bio Zero in a separate business area was to increase the transparency of BICO's financial profile, as Bio Zero has a different business model and financial profile compared to our instrument companies due to its project-based business, with significant fluctuations in revenues depending on project starts. Primarily, this relates to BioZero having a percentage of completion revenue recognition model, which creates significant revenues when a project is started and when instruments for the projects are typically acquired. And as mentioned, in this quarter we had fewer project starts, impacting revenues negatively. Furthermore, for the quarters to come, Lab Automation will have tough comparable figures due to the large order of $28 million at the end of 2023, which had a significant positive effect on the first half of 2024 financials. Maria will comment in detail on the business areas to give you some more in-depth information, especially with regards to Lab Automation and the project-based business models. Lastly, unlike many of our industry peers, we have seen improved sales in our companies that are more focused on consumable sales. And if we move on to profitability, adjusted EBITDA for Q3 amounted to 40 million, corresponding to a margin of 8%. EBITDA amounted to 30 million, also corresponding to a margin of 8%. All business areas were profitable in the quarter. The margin drop of 8% is explained by weaker sales development compared to last year and, as previously mentioned, driven by a continued weak market in the academia, research, and diagnostics segments due to ongoing CapEx constraints as well as fewer project starts in Lab Automation. This decrease in sales was partially offset by better cost control, an improved product mix, and lower personnel costs. As always, and it's worth repeating, staying on course with cost control is a priority across the group. Staying on course with cost control is always a priority across the group. And if we move on to the next slide and our cash flow, the cash flow from operating activities for the quarter amounted to 45 million. This includes a positive effect from changes in working capital of 33 million. Out of this, 17 million was related to increases in operating receivables. Inventories decreased by 90 million, continuing the positive trend of decreased inventory, and operating liabilities increased by 31 million. Investments in tangible CapEx amounted to 10 million, and investments in intangible CapEx amounted to 17 million for the second quarter in a row. We didn't pay out any earnouts. Total estimated remaining earn-out payments amounted to 8 million. Total cash flow during Q3 amounted to -1 million, and cash reserves by the end of September amounted to 682 million. This slide shows the development in net working capital between Q3 2023 and 2024. During this period, net working capital has decreased from 550 million to 456 million and has been stable between 20 to 24% of sales. To conclude, BICO has for the past quarters shown that the actions implemented in 2023 to improve working capital were successful. We have continued to work diligently on this during the year as part of our operational excellence activities, and because the levels of net working capital are now in line with industry peers. Maria will now comment on our three business areas. Performances.

Maria Forss
16:44 - 18:57

I will guide you through our business areas for the third quarter, but first, I would like to repeat the rationale behind our new business area structure. This was introduced during Capital Markets Day. And on this slide, you can see the former business area structure, which we have reported on since quarter one of 2022, namely Biosciences, Bio Automation, and Bioprinting. To better reflect the updated strategy in our commercial focus, we decided to introduce new business areas. And here you can see the new business area structure, which we presented at the Capital Markets Day. As Lab Automation is one of the cornerstones in our updated strategy, we have decided to introduce Lab Automation as a new business area, which will comprise our market-leading company with integrated Lab Automation solutions. In addition to being a cornerstone in our strategy, this will also increase the transparency of BICO's financial profiles as Biosphere has a different business model and financial profile compared to instrument companies due to a project-based business, as Jacob Thordenberg mentioned. Additionally, we introduced Life Science Solutions as a new business area where we will offer instruments, selected workflows, and complementary offerings such as consumables, software, and services. Our third business area, Bioprinting, we kept intact, and this holds a differentiating position in the portfolio, creating opportunities for the lab of the future. Let's now move on to see how the business areas performed. The revenue for the business area Lab Automation was impacted by fewer product starts during quarter three compared to previous quarters, which also affected the profitability levels compared to the corresponding quarter last year. And it's important to highlight that the biosphere has a project-based business with significant fluctuations in revenues between quarters. Hence, looking at an individual quarter comparison is less relevant. The business area reported net sales of 101,000,000 in quarter three, and the organic growth in the segment was -25%. The delay in project starts is the main reason for the deviation in the isolated quarter.

Unknown 1
18:59 - 18:59

And for reference, a more relevant view when looking at the first nine months of 2024 shows that the business area delivered an organic growth of 26% compared with the corresponding period last year.

Maria Forss
18:59 - 24:51

For reference, a more relevant comparison when looking at the first nine months of 2024 shows that the business area delivered an organic growth of 26% compared with the corresponding period last year. So, we continue to see a strong trend and demand for integrated Lab Automation solutions. However, the sales cycles for large orders in the pharma sector are currently longer. If we move on to life science solutions in quarter three, this business area's net sales amounted to 238 million. The organic growth was -12% and adjusted EBITDA was 13 million, which corresponds to a margin of 13%. The business area exhibited weak development in the company's Signal and Echo divisions, where Signal was hampered by a slower diagnostic market, and Echo was impacted by a sluggish academia and research segment. Profitability levels were kept at positive double digits, which was the result of strict cost control actions. To decrease the cost base and strengthen the commercial offerings, measures are in place for CELLINK, and positive effects have gradually begun to materialize. Let us now move on to the results for our area. Bioprinting, the Bioprinting business, reported net sales of 159,000,000 in quarter three. The organic growth in the segment was -3%, and the adjusted EBITDA was 24 million, corresponding to a margin of 15%. Martex products, which are mainly consumables, showed healthy demand during the quarter while sales levels were impacted by a continued lower demand from academia and research. And it's important to highlight that the corresponding quarter last year was a very strong one, both from sales and profitability perspectives. As mentioned earlier, BICO has entered into an agreement after the end of the quarter to divest Nanoscribe, and we have also mentioned that we were planning this move. CELLINK has announced further rightsizing and launched a sharpened commercial agenda. And before we move on into the Q&A, I would like to comment on the development of our strategic priorities, present our strategic agenda, and comment on our financial targets. So if we move on to the next slide, I will give you a brief update about the development on our four strategic priorities. Commercial excellence, which is our key priority, has been reinforced with five focus areas. And during the quarter, two global skills teams focusing on lead generation and sales excellence were launched. We have also established teams across the group developing common processes and tools for digital marketing, cross-company lead generation, and designing a global partnership development program. Commercial excellence will continue to be our highest priority, and we will continue to roll out initiatives for the strategic review. It was also announced after the end of the quarter that BICO bought back convertible bonds. As Jacob has commented upon and as we communicated during our Capital Markets Day, and also mentioned by Jacob in this presentation, we continually assess the strategic fit across our portfolio of assets and consider options that are positive for shareholder value. And in this context, we continue to see inbound interest for many of our assets to further support people and culture with new core values. Trust. Focus, collaboration, and grit were launched to build a high-performance culture and are now being implemented across the BICO Group. And lastly, for operational excellence improvements, we continued our diligent work to reduce inventory. We're implementing a global QA and Regulatory Affairs organization, as well as working with contract development and manufacturing organization solutions. If we move on to the next slide. To repeat the core of our updated strategy, we combine our knowledge about the market, focusing on where our strengths and competitive advantage lie with our product offering; this is the basis for our choice of strategic direction. Lab Automation is the first cornerstone aimed at providing full workflow automation solutions in key processes, and it acts as the main enabler of group synergies. Bioprinting holds a differentiating position in BICO's portfolio, creating opportunities for the lab of the future. These cornerstone offerings are enabled by a range of products and services. Instruments are provided as a standalone product or paired with other offerings. Consumables are tactically positioned to augment the offering, provide relevant end-to-end solutions, and achieve recurring revenue patterns and streams. Software and associated services are delivered alongside hardware to bolster customer stickiness, and that is a main driver of differentiation. And lastly, service offerings that keep BICO relevant even after hardware purchases. All in all, this leads us to our strategic house. Here is our updated strategy on the page. Our new vision is to enable and automate the life science lab of the future, and our new mission is to be the first choice Lab Automation partner and provider of selected workflows to pharma and biotech. Our strategic priority is commercial excellence. We have reinforced our approach with five focus areas. We have our four core values, as well as the impact and difference that we make for our customers with our solutions. And at the bottom, you see our three financial targets. And we'll now hand over to Jacob to comment on the development of these.

Jacob Thordenberg
24:51 - 25:56

Thank you, Maria. The financial targets have been valid since 2023 and were reiterated during our Capital Markets Day. Since they are still relevant, we want to deliver on these existing targets before setting new ones, which we intend to define when the current targets have been achieved. I will now comment on the development on a rolling 12-month basis for the growth target. The outcome was -4.1%. The outcome is below target given the soft market for instrument sales, primarily in academia, research, and diagnostic segments due to CapEx constraints. For the profitability target, the outcome for adjusted EBITDA was 5.8%. The outcome is below target and negatively impacted by slower sales, affecting the debt target. We achieved 4.8% for adjusted EBITDA. The negative cash flow in 2024, combined with a weaker market in terms of sales, has increased the ratio over time. I will now hand back again to Maria for some final remarks.

Maria Forss
25:57 - 26:37

Thank you, Jacob. So our updated strategy was launched by the end of quarter three. And with the divestment of Nanoscribe, repurchase of convertible bonds, the further rightsizing, and a more focused commercial agenda for CELLINK, we are in the beginning of the execution phase. When looking at the financial targets and considering the tough market we're operating in, with spending and CapEx restraints, along with weaker demand from China. We are confident that our updated strategy will support us in achieving our financial targets in the long term, and that we're moving in the right direction. This was our final slide before the Q&A session, and I will hand over to Financial Hearing's host for further instructions.

Operator
26:41 - 27:03

If you wish to ask a question, please dial Pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Richard Andy Kranz from Handelsbanken. Please go ahead.

Richard Andy Kranz
27:06 - 27:43

Good morning. Good morning, and thank you for taking my questions. I have a few, please. Starting off with the CELLINK additional restructuring, it would be interesting if you could quantify the restructuring impact on a group level, both in terms of the top-line impact from product pruning and, most importantly, on the OpEx side. And when do you expect that business area to be profitable? And the follow-up question on that is how much similar type of restructuring and cost-cutting do you have left across the group at this point? Thank you.

Jacob Thordenberg
27:45 - 28:31

All right. Good morning, Richard. That's what I counted; it seems to be three questions. So, the top-line impact includes cost and similar cost rightsizing activities. And for the top-line impact, I believe that we have seen most of this impact in the past quarters. And what we intend to do now is to undertake further rightsizing, given that we believe we have reached a stable level of sales in CELLINK. And to put that into perspective, in terms of group costs, it does not have a material impact. So we're talking about roughly a saving of 40 million Swedish kronor on an annual basis. And when it comes to similar activities, there are no other sort of right-sizing activities currently active in the group.

Richard Andy Kranz
28:33 - 28:42

If you wish to withdraw your question, please dial the Pound Key six on your telephone keypad. Uh. Very helpful. Uh, do you anticipate that there will be a need for additional rightsizing activities, uh, from here?

Jacob Thordenberg
28:43 - 29:19

Uh, I mean, we should never exclude that, but I wouldn't say so. I would say that our main focus right now is to concentrate on operational excellence and achieve more efficiencies across the group, rather than further right-sizing. But we will continue to work in our operational excellence program, finding synergies between the groups, uh, between the companies, etc. . So we will definitely work hard to stay in cost control, of course, but also find more efficiencies, but not necessarily additional rightsizing activities.

Richard Andy Kranz
29:21 - 29:55

That's clear. Thank you. Um, so NIH funding exposure is less than 5% at a group level within the academic government segment. So what data points or signals are you looking for to identify? To determine if we can see an improvement in that market heading into next year, it would be interesting to hear if we could have any insights on the timing, such as budget renewals or other key data points to look out for in the academic segment to improve.

Maria Forss
29:57 - 30:41

When it comes to NIH funding, usually when researchers apply for grants, they are provided grants that are between 1 and 3 years long. Um, and uh, through our CRM system and our diligent work with customers, we are constantly monitoring what's happening in that part of the market. And, um, we will see what happens with the new administration with Trump coming into place. The message so far has been that they should drive efficiencies, and hence we're well placed with our portfolio. That is driving efficiency in the lab for the future. So, um, that's all we know for now.

Richard Andy Kranz
30:43 - 31:01

All right. Thank you. And um, in Q1, I believe you mentioned some positive signs from Europe and North America. I guess that's not really the case anymore. And it would be interesting to hear what parts of the business deteriorated compared to the wording in conjunction with Q1. Thank you.

Jacob Thordenberg
31:08 - 31:14

Uh, could you repeat that question? Because I'm not sure we see the same pattern here. Could you clarify what you mentioned in Q1?

Richard Andy Kranz
31:14 - 31:38

In the CEO letter in Q1, you mentioned there were some positive signs in Europe and North America, and I was just following up to see if that still holds true, as it doesn't seem to be the case anymore. And it would be interesting to hear what parts of the business have sort of deteriorated throughout the year compared to some of the positive signals you mentioned.

Jacob Thordenberg
31:38 - 32:17

But I wouldn't call it parts of the business; rather, I would phrase it differently. There has been a sense of optimism around a market recovery by the end of 2024, and this applies not only to BICO but to the industry in general. And I think what many have seen, including BICO, is that the market has continued to be soft. And I think it's rather that. But, uh, our text or our comments in Q1 indicated sort of positive signs that we saw in the market. But we have unfortunately, like many of our peers, continued to see a soft market.

Maria Forss
32:19 - 32:51

We can also comment on the fact that the part of the business more focused on consumable sales is now showing a better gradual increase than the more instrument-focused side of the business. And this is also in line with what our peers have reported. And usually what you see in this type of macro environment is that consumables start to improve first, and then in the next wave, instruments usually follow.

Richard Andy Kranz
32:53 - 33:20

Perfect. Very clear. And a final question from me on Lab Automation: could you roughly quantify how much of the $28 million order announced last year has been recognized in the P&L so far? In the press release, it was stated that the vast majority of the project will be carried out and invoiced during 2025. So just following up a little bit on that order, and also if you could add, uh, and describe sort of the pipeline for Bio X projects at the moment. Thank you.

Unknown 1
33:22 - 33:22

Yeah.

Jacob Thordenberg
33:22 - 34:00

So when it comes to the order 1 in 2023, I want to give you sort of a split on how much of that has been recognized in the first half of 2024, but a significant share of the revenues from that order was recognized in the first half of 2024. Referring to what I mentioned earlier in the call, when we buy instruments, typically we also have significant revenue recognition. We continue to see a strong trend for Lab Automation and a solid pipeline of projects. But Maria, do you want to give some further insights?

Maria Forss
34:00 - 34:55

I think again, it's worth reiterating the fact that a single quarter is not relevant. We should look over time. And we had a growth, uh, year to date of 26% in that, um, business area. And, um, given that many of these projects are large in scope, they span over multiple quarters. And that means that when there is, pressure on cost control, also in the pharma industry, they will take longer to complete procurement and purchase orders than normal. And in quarter three there were fewer project starts. And that was one of the reasons why we separated the Lab Automation business due to its lumpiness and project-based nature. So we continue to see strong demand for lab automation solutions in the market. And we're only at the beginning of the Lab Automation era.

Richard Andy Kranz
34:57 - 34:59

Great. Thanks for taking my questions.

Unknown 1
35:00 - 35:00

Thank you.

Operator
35:04 - 35:09

The next question comes from Ulrich Trattner from Carnegie. Please go ahead.

Unknown 1
35:12 - 35:13

Great.

Ulrich Trattner
35:13 - 35:57

Thank you very much. Um, another question on lab automation. I know it's a project-based business and the lumpiness attached to it. And you generate significant margins, as you mentioned, when you're launching a new product and purchasing an instrument. Now you're stating, Maria, here in the CEO letter, that you're seeing a slower number of starts for new projects. Should that, in turn, be interpreted that Q4 will most likely continue on the same trend on the margin side that we'll see in Q3? We're now beyond sort of the midpoint of this quarter. So what are you currently seeing?

Maria Forss
35:59 - 36:14

As you know, we never guide moving forward as Jacob Thordenberg presented during the presentation. We had very strong quarters in Q4 last year and also Q1 this year when it comes to Lab Automation.

Ulrich Trattner
36:16 - 36:45

Okay, um, an additional question on the CELLINK right-sizing and cutting 20% of employees. Could you quantify how many employees this entails, and also confirm if this is subject to union negotiations? So were the savings in the range of 40 to 50 million. Where are we at in terms of timing of seeing these realized?

Maria Forss
36:47 - 37:18

So two questions. I'll start with the first one. When it comes to 20% of the workforce. And as you can see in the annual report from last year, CELLINK has roughly 100 employees. So it's roughly 20, uh, colleagues that we're talking about. And, uh, given that this is part of union negotiations, most of the staff are based in Sweden, which means that we will start to see these effects. Late quarter one. Early quarter two.

Unknown 1
37:20 - 37:21

We're now beyond the midpoint of this quarter.

Ulrich Trattner
37:21 - 37:49

Um, and last question on my end, uh, I know the big improvement in cash flow, and I know that you're happy with the level of working capital in percentage of sales. So if you were to focus on the CAPEX part instead, and we have reached some type of new lower level in CAPEX spend, is this the maintenance level that we should expect going forward as well?

Jacob Thordenberg
37:51 - 38:15

When it comes to sort of tangible CapEx? I would say yes. I mean, we are not a tangible CapEx business. I think the other question is, of course, how much we will spend on capitalized R&D, and that is something that we're currently looking into.

Ulrich Trattner
38:17 - 38:27

And would you say that that would materially change the current dynamic of CAPEX, or is it just in the magnitude of a small change? I would say smaller adjustments.

Jacob Thordenberg
38:28 - 38:30

I don't expect any material changes. No.

Unknown 1
38:32 - 38:33

Okay, great.

Ulrich Trattner
38:33 - 38:35

That was all questions on my end. Thank you.

Unknown 2
38:35 - 38:36

Thank you.

Operator
38:40 - 38:47

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Maria Forss
38:51 - 39:12

Thank you for all the questions. And thank you, everyone, for joining us today. Before we end, we would like to update you on our financial calendar. Our next earnings call, which we will host, will be for our year-end report and will take place on February 19th, 2025. So together with Jacob, I would like to wish everyone a great Tuesday. Thank you and goodbye.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…